Congressional lawmakers strike back at Biden admin's 'march-in' proposal to corral drug costs

As the Biden administration’s exploration of “march-in rights" draws support from powerful entities like the Federal Trade Commission (FTC), a group of lawmakers on both sides of the aisle have warned the approach could “hamstring” U.S. innovation.